Caladrius Biosciences (CLBS) Announces IDSMB Recommendation to Commence Enrollment of CLBS03 Phase 2 as T2D Treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall St drops as Meta Platforms, economic data weigh
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Dollar firmer on higher U.S. inflation; yen sinks vs euro, US currency
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Caladrius Biosciences Begins Enrollment of Second Cohort of Phase 2 Trial of CLBS03 as a Treatment for Type 1 Diabetes Following Favorable Safety Data from First Cohort
October 31, 2016 7:30 AM EDTEarlier assessment of clinical safety permits acceleration of trial timeline
Sanford Research to Provide Operational Support at its Clinical Sites for Remainder of Trial
BASKING RIDGE, N.J., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ: CLBS) (Caladrius or the Company), a cell therapy company combining a unique, promising therapeutic development pipeline with an industry-leading development and manufacturing services provider through its subsidiary PCT, LLC a Caladrius Company (PCT), today announced that the independent Data Safety Monitoring Board (DSMB) for its Phase 2, The Sanford Project: T-Rex Study recommended that the trial... More
